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Abstract
Background: The presence of an oligodendroglial component within a glioblastoma multiforme
(GBM) is considered a prognostically favorable factor, but the clinical outcome of patients with
glioblastoma multiforme with oligodendroglial component (GBMO) after combined post-operative
radiotherapy and chemotherapy has rarely been reported.
Methods: We analyzed overall and progression-free survival in a group of ten consecutive patients
initially diagnosed with GBMO between 1996 and 2004 (4.2% of all GBM patients). Median (range)
age was 54 (34–73) years, 90% were resected and median radiotherapy dose was 54 (45–60.6) Gy.
80% of patients received post-operative chemotherapy with nimustine (ACNU) and VM26
(teniposide) for a median of 3.5 (1–6) cycles, the remainder were treated with post-operative
radiotherapy alone. All specimens were reviewed by an experienced neuropathologist.
Results: Neuropathological re-evaluation revealed GBM with an oligodendroglial component of
30% or less in five cases, predominant oligoastrocytic tumors with focal areas of GBM in four
patients and WHO grade III oligoastrocytoma with questionable transition to GBM in one patient.
Four of ten patients were alive at at 40, 41, 41 and 82 months. The median overall survival (Kaplan-
Meier) was 26 months, the 2-year survival rate was 60% (progression-free survival: 9.8 months and
40%, respectively).
Conclusion: In conclusion, patients with GBMO treated with post-operative radiotherapy and
chemotherapy with ACNU/VM26 had a better prognosis than reported for GBM in modern
chemoradiation series.
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Background
Although glioblastoma multiforme with oligodendroglial
component (GBMO) is not considered as a distinct dis-
ease entity in the most recent World Health Organization
(WHO) classification of central nervous system tumors
[1], the increased chemosensitivity and radiosensitivity of
WHO grade III anaplastic oligodendrogliomas [2,3] has
led to the assumption that patients with GBMO might
similarly have a better prognosis than patients with classic
glioblastoma multiforme (GBM). To the authors' knowld-
edge, data from phase III clinical trials on the outcome of
the subgroup of patients with GBMO have not been pub-
lished. In trial 83-02 of the Radiation Therapy Oncology
Group (RTOG), a four-arm randomized phase I/II trial
assessing different radiotherapy fractionation schedules
with carmustine (BCNU) chemotherapy in all arms, the
median survival of 14.3 months in GBMO was signifi-
cantly longer than the 10.4 months observed in classic
GBM [4]. The 2-year survival rates were 35% and 4%,
respectively.
Until the recent establishment of combined chemoradia-
tion with temozolomide as a new treatment standard [5],
the use of chemotherapy in GBM patients was not gener-
ally recommended. A meta-analysis of randomized con-
trolled trials of mostly nitrosurea-based chemotherapy in
malignant glioma found an absolute increase in overall
survival of 6% at one year and of 4% at two years in gliob-
lastoma patients treated with chemotherapy [6]. In Ger-
many, combination chemotherapy with nimustine
(ACNU) and teniposide (VM26) was a preferred protocol
in glioblastoma patients in whom chemotherapy was
indicated, leading to a median overall survival of 17.3
months in glioblastoma in the NOA-01 trial [7]. It has
been the policy in the authors' institution to recommend
post-operative chemotherapy with ACNU and VM26, in
addition to radiotherapy, if patients with GBMO were in
sufficiently good general general condition (Karnofsky
index of at least 70). We report here the clinical outcome
of a series of ten consecutive patients with GBMO treated
between 1996 and 2004.
Methods
Patients and treatment
The charts of all patients with a diagnosis of GBM referred
to the Dept. of Radiation Oncology, University of Würz-
burg, were reviewed regarding a histopathological diagno-
sis of GBMO. For initial histopathological evaluation,
immunohistochemistry for the markers glial fibirillary
acidic protein (GFAP), Ki-67, p53 or CD68 was routinely
performed by standard techniques. Although there is no
uniform definition of GBMO, all patients in whom the
initial histopathological report – on which treatment deci-
sions were based – described a population of cells with
oligodendroglial features next to a population of astro-
cytic and anaplastic glioma cells, with obvious features of
highest malignancy typically found in GBM, were
included in the study cohort, regardless of the extent of
the oligodendroglial component [8]. Of 240 patients with
GBM treated during the period studied, n = 10 (4.2%)
were found to have an oligodendroglial component
described in the initial pathology report. Histopathologi-
cal slides of these ten patients were reviewed by an experi-
enced neuropathologist (W. R.), who was blinded to the
clinical outcome of the patients, on the basis of the WHO
classification of 2000 [1]. The results of this re-evaluation
did not affect inclusion of patients in the present analysis.
The 1p/19q status was not determined as part of the
present study.
A summary of patient and treatment characteristics for
this group of GBMO patients is given in Table 1. Charac-
teristics of individual patients are shown in Table 2.
Patients were assigned to defined prognostic groups based
on the RTOG recursive-partioning analysis data for malig-
nant glioma [9]. Treatment details are listed in Tables 1
and 2. Radiotherapy was administered as a 3-D conformal
treatment, the target volume being based on contrast-
enhanced planning computed tomogrophy (CT) and pre-
operative imaging. Chemotherapy with ACNU (90 mg/m2
iv, day1) and VM26 (60 mg/m2, days 1 to 3; both drugs
given in six-week intervals) was usually initiated after
completion of radiotherapy. In general, it was aimed to
administer six cycles of chemotherapy. In three patients,
Table 1: Overview of patient and treatment characteristics
age at diagnosis (years) median (range) 54 (34–73)
surgical procedure biopsy resection 1/10 (10%)
9/10 (90%)
total RT dose (Gy) median (range) 54 (45–60.6)
adjuvant chemotherapy with ACNU/VM26 8/10 (80%)
no. of adjuvant cycles median (range) 3.5 (1–6)
≥ 4 adjuvant cycles 4/10 (40%)
Overview of patient and treatment characteristics for n = 10 consecutive patients with glioblastoma multiforme with oligodendroglial component 
(GBMO).B
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Table 2: Characteristics, treatment and clinical course of individual patients
RPA class no. sex age (years) result of neuropathologic reevaluation (% of 
oligodendroglial component, where applicable)
surgery total/daily RT 
dose (Gy)
total/pre-RT adjuv. cycles 
ACNU/VM26 (reason for 
termination)
salvage treatment overall 
survival 
(months)
III 1 m 34 GBM with extensive oligodendroglial component (30%) resection 55.1/2 × 1.8 6 -- 40+
2 f 39 grade III oligoastrocytoma with transition to GBM resection 60.6/2 × 1.8 3 (thrombo-cytopenia III°) 17 × TEM 41+
IV 3 f 51 small-cell GBM with extensive oligodendroglial component 
(75%)
resection 53.4/2 × 1.8 2/1 (leuko-cytopenia II°) 1 × ACNU/VM26 47
4 m 53 anaplastic oligodendroglioma with focal transition to GBM resection 59.4/1.8 5/1 -- 82+
5 f 73 GBM with oligodendroglial component (30%) resection 59.4/1.8 4/2 reirradiation (6 × 5 
Gy), surgery, 1 × TEM
26
V 6 f 54 anaplastic oligodendroglioma with transition to GBM resection 45/3 6 -- 41+
7 f 62 GBM with minor oligodendroglial component resection 54/2 × 1.8 2 (progression) 3 × TEM 13
8 f 54 GBM with oligodendroglial component (20%) resection 45/3 1 (thrombo-cytopenia IV°) -- 10
VI 9 m 60 very small tissue sample, anaplastic oligodendroglioma, GBM 
possible
open biopsy 54/2 × 1.8 -- -- 7
10 m 72 GBM with minor oligodendroglial component (less than 5%) resection 45/3 -- -- 10
Patient and treatment characteristics and clinical course of n = 10 consecutive patients with glioblastoma multiforme with oligodendroglial component. The results of the neuropathological re-evaluation at the time 
of the present analysis are summarized (GBMO; RPA: recursive partitioning analysis according to [9], RT: radiotherapy, ACNU: nimustine, VM26: teniposide, TEM: temozolomide).BMC Cancer 2006, 6:247 http://www.biomedcentral.com/1471-2407/6/247
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one or two cycles were given post-operatively before radi-
otherapy (Table 2).
Statistics
Overall survival was studied as the main end point. Over-
all survival status was obtained from local resident's regis-
tration offices. Progression-free survival was used as a
secondary endpoint. The dates of diagnostic imaging stud-
ies were considered in the calculation of progression-free
survival. Progression was defined as an unequivocal
increase in the size of the contrast-enhancing lesion on CT
or magnetic resonance imaging (MRI), typically per-
formed in three-month intervals, leading to a considera-
tion of salvage treatment options in the interdisciplinary
tumor board. Actuarial survival rates were calculated from
the time of histological diagnosis using the Kaplan-Meier
method. Patients consented to anonymous data analysis
as part of the treatment contract with the university hospi-
tal.
Results
The clinical course of individual patients is shown in
Table 2. Eight of ten patients with GBMO received a
median of 3.5 (range 1 to 6) cycles of chemotherapy with
ACNU/VM26 as part of their adjuvant treatment. At the
time of analysis, 4 of 10 patients were alive at 40, 41, 41
and 82 months. The Kaplan-Meier curves of overall sur-
vival and progression-free survival are shown in Fig. 1. The
median overall survival of GBMO patients was 26
months. Overall survival at two years and at four years was
60% and 25%, respectively. The median progression-free
survival was 9.8 months. At two and four years, 40% and
26.7% of patients, respectively, were free of progression.
Histopathological re-evaluation of all specimens by an
experienced neuropathologist revealed different degrees
of oligodendroglial component within the tumor tissue.
The grading of results of immunohistochemistry for
GFAP, Ki-67, p53 and CD68 in individual patients is given
in Table 3. Whereas five tumors were classified as GBM
with an oligodendroglial component of 30% or less, the
others were diagnosed as containing a predominant WHO
grade III oligodendroglial or oligoastrocytic component.
In four of the latter group, features of WHO grade IV GBM
were seen. In one case, for which only very limited biopsy
material was available, anaplastic oligodendroglioma was
diagnosed upon review without confirmation of GBM.
The overall survival times for patients with GBM and oli-
godendroglial component of 30% or less were 10, 10, 13,
26 and 40+ months as compared to 7, 41+, 41+, 47, and
82+ months for patients with a predominant WHO grade
III oligodendroglial or oligoastrocytic component.
Discussion
Before the recent introduction of combined radiochemo-
therapy with temozolomide [5], the use of chemotherapy
in GBM was not universally recommended. The presence
of an oligodendroglial component within an astrocytic
tumor with features of a WHO grade IV glioblastoma,
however, has been regarded by some authors as an indica-
tor of increased chemosensitivity of such tumors. This
assumption was based on the high response rates of WHO
grade III anaplastic oligodendroglioma, as compared to
grade III anaplastic astrocytoma, established in phase II
trials in the 1990s [2]. Two recent randomized phase III
trials of adjuvant PCV in anaplastic oligodendroglioma
and anaplastic oligoastrocytoma, RTOG 94-02 and
Overall survival (A) and progression-free survival (B) of n =  10 consecutive patients with glioblastoma multiforme with  oligodendroglial component (GBMO) Figure 1
Overall survival (A) and progression-free survival (B) of n = 
10 consecutive patients with glioblastoma multiforme with 
oligodendroglial component (GBMO).
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EORTC 26951, found a significant improvement in pro-
gression-free survival (2.6 vs. 1.9 years and 2.0 vs. 1.1
years, respectively) after addition of PCV chemotherapy,
but so far no effect on overall survival [10,11]. The clinical
outcome of patients with WHO grade IV GBMO has rarely
been reported. Median survival rates in the small series
available in the literature (Table 4) ranged between 14
and 26 months, 2-year survival rates between 20% and
58%. The overall survival of 10 consecutive patients with
GBMO in the present series (median 26 months, 60% at
two years) compares favorably to these GBMO series and
to the outcome of all GBM patients in large clinical trials,
including the temozolomide radiochemotherapy arm in
EORTC 26981 and the ACNU/VM26 arm in the NOA-01
trial [5,7].
The favorable survival rates in the present series of
patients with GBMO may be a result of a good response of
these tumors to initial multi-modality management with
surgery, post-operative irradiation and chemotherapy
with ACNU/VM26 (where feasible), but may also be
influenced by the criteria for patient selection and the
response to salvage therapy. Although the patients now
analyzed were retrieved from the database of the radiation
oncology department it appears unlikely that this intro-
duced a relevant selection bias. Post-operative radiother-
apy is a standard treatment in GBM and the reported
median survival rate of all patients with GBM treated with
radiotherapy in this department between 1990 and 1999
was 11.5 months [12]. The term GBMO has not been uni-
formly defined and especially the distinction of GBMO
from anaplastic oligoastrocytoma is generally considered
difficult [1,8,13]. However, nine of ten patients included
clearly had tumors with components of highest malig-
nancy, as found in grade IV GBM. In one patient with very
limited biopsy material, the GBM component within a
grade III oligoastrocytoma was judged as uncertain upon
review. The fact that the patients now analyzed were actu-
ally considered to have GBM at the time of adjuvant treat-
ment planning is underscored by the use of accelerated
radiotherapy schedules, limiting the treatment duration
to approximately three weeks, in 8 of 10 patients – an
approach reserved for grade IV tumors at the authors'
institution.
Within the limited patient cohort studied, the extent of
the oligodendroglial component appeared to be linked to
prognosis. Whereas only one of five patients with 30% or
Table 4: Treatment results of selected series of GBM and GBMO
series patient group n treatment median overall 
survival (months)
2-year overall 
survival
reference
NOA-01 all GBM 154 post-OP RT + ACNU/VM26 17.3 25% [7]
EORTC 26981 all GBM 287 post-OP RT + TEM 14.6 26.5% [5]
RTOG 83-02 GBMO 23 post-OP RT + BCNU 14.3 (3-year survival: 
35%)
[4]
retrospective GBMO 12 resection + RT, chemo in 2/12 26 58% (data taken 
from graph)
[8]
retrospective GBMO 11 post-OP RT in 65% (total group) 17.7 20% (data taken 
from graph)
[18]
retrospective GBMO 5 post-OP RT in 80% 16.2 n. a. [19]
present series GBMO 10 post-OP RT + ACNU/VM26 (8/10) 26 60%
Overview of treatment results in glioblastoma multiforme (GBM) and GBM with oligodendroglial component (GBMO) from selected series (RT: 
radiotherapy, ACNU: nimustine, VM26: teniposide, TEM: temozolomide, n. a.: not available).
Table 3: Results of immunohistochemistry in individual patients with GBMO
patient no. GFAP Ki-67 p53 CD68
1+ +++ + n .  a .
2 + +++ + ++
3 ++ ++ n. a. +
4 n. a. n. a. n. a. n. a.
5 ++ + n. a. ++
6 + +++ n. a. n. a.
7 ++ +++ +
8 ++ +++ +
9 ++ + n. a. ++
10 + ++ n. a. n. a.
Results of immunohistochemistry for glial fibrillary acidic protein (GFAP), Ki-67, p53 and CD68 in individual patients with glioblastoma multiforme 
with oligodendroglial component (GBMO; patient numbers correspond to Table 2). Staining was scored as weak (+), intermediate (++), strong 
(+++) or not available (n.a.).BMC Cancer 2006, 6:247 http://www.biomedcentral.com/1471-2407/6/247
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less oligodendroglial cells survived for more than two
years, this was true for four of five patients with a predom-
inant oligodendroglial component. Obviously, such
quantifications must be regarded with caution as percent-
ages for particular cell types on sectioned material need
not be representative of the overall tumors.
GBMO tumors have been reported to frequently contain
molecular genetic alterations associated with increased
chemosensitivity in oligodendroglial tumors such as a
loss of heterozygosity (LOH) on chromosome arms 1p
and 19q [8,13]. Microarray analysis of gene expression
has been suggested as a method to distinguish "classic
GBM" tumors from a group termed "non-classic" GBM
with a better prognosis [14]. In the present series, identi-
fication of an oligodendroglial component on routine his-
topathological evaluation of tumor sections was
apparently able to select a patient group with a better
prognosis than in classic GBM.
In some of the previous series of patients with GBMO,
patients were mostly treated with surgery and post-opera-
tive radiotherapy, but without chemotherapy. This may in
part explain the favorable results of the present analysis.
The low rate of patients surgically treated with biopsy only
(1/10 in the present series) is comparable to the series of
Kraus et al. [8] (Table 3) where all patients were resected
such that a particularly aggressive surgical approach in the
present patient group appears to be an unlikely explana-
tion of the high survival rates.
The progression-free survival observed may be regarded as
a better indicator of the efficacy of the initial treatment
regimen. The median progression-free survival of 9.8
months is also longer than that seen in large trials of GBM,
e. g. 6.9 months in the temozolomide arm of EORTC
26981 [5]. This suggests that the response of GBMO to
ACNU/VM26 might be better than that of GBM in general
to temozolomide. Clearly, the use of salvage treatments
including surgery, stereotactic hypofractionated reirradia-
tion [15] and temozolomide chemotherapy has led to
prolonged survival in individual patients failing early after
initial post-operative chemotherapy with ACNU/VM26
(Table 2). The efficacy of temozolomide as an initial treat-
ment or as salvage therapy for GBMO has not been pub-
lished to our knowledge.
The information gained by the present study is limited by
the small number of patients who, nevertheless, represent
the total number of this entitity from an eight-year period
at a university center. A similar analysis focussing on spe-
cific effects of the addition of chemotherapy in patients
with GBMO would be possible in subsets of patients from
recently completed randomized trials in glioblastoma. It
would, therefore, be of interest to analyze specifically the
clinical course of GBM patients with an oligodendroglial
component treated with temozolomide in EORTC 26981.
It is also unknown whether patients with GBMO might
benefit from an escalation of radiation dose, an approach
currently considered not benefitial in GBM [16], or from
high-dose chemotherapy protocols as investigated in ana-
plastic oligodendroglioma [17].
Conclusion
In summary, the prognosis of patients with GBMO treated
with post-operative radiotherapy and chemotherapy with
ACNU/VM26 was favorable compared to published data
for GBMO treated mostly with post-operative radiother-
apy alone and compared to GBM treated with post-opera-
tive radiotherapy and different regimens of
chemotherapy. The outcome of GBMO after radiotherapy
with concomitant and adjuvant temozolomide, the cur-
rent standard for GBM, is not known. A superiority of
ACNU/VM26 over temozolomide in GBMO can not be
advocated. From our experience, post-operative chemo-
therapy should be offered to patients with GBM whenever
possible in the presence of an oligodendroglial compo-
nent.
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